Destiny Pharma narrows losses; pauses study on lead drug
Clinical stage biotechnology Destiny Pharma reported narrower losses on lower share-based payment expenses. The company paused a clinical study on its lead drug, but said...
Wed, 29/04/2020 - 09:31